Prophylactic use of cardiac implantable defibrillators in patients with severe left ventricular dysfunction: How to deal with decision making among guidelines, clinical practice, ethical problems, and limited economic resources;Uso profilattico del cardioverter-defibrillatore impiantabile nei pazienti con grave disfunzione ventricolare sinistra: Come districarsi tra linee guida, pratica clinica, problemi etici e limitazione delle risorse

Giornale Italiano di Cardiologia

Volumn 9, Issue 5, 2008, Pages 338-354

  Berisso, Massimo Zoni ^a   Caruso, Davide ^a   Canonero, Daniele ^a   Setti, Sergio ^a   Domenicucci, Stefano ^a  

^a Ospedale Padre Antero Micone   (Italy)

Author keywords

Guidelines; Implantable cardioverter defibrillators; Sudden cardiac death

Indexed keywords

ARTICLE; CLINICAL PRACTICE; COMORBIDITY; COST BENEFIT ANALYSIS; DEFIBRILLATOR; ECONOMIC ASPECT; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MEDICAL DECISION MAKING; MEDICAL ETHICS; PATIENT SELECTION; PRACTICE GUIDELINE; PROPHYLAXIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SUDDEN DEATH; TREATMENT INDICATION;

ADULT; AGED; AGED, 80 AND OVER; COSTS AND COST ANALYSIS; DEATH, SUDDEN; DEFIBRILLATORS, IMPLANTABLE; HUMANS; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; SEVERITY OF ILLNESS INDEX; VENTRICULAR DYSFUNCTION, LEFT;

EID: 48249140639     PISSN: 18276806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (175)

1. Myerburg RJ, Castellanos A. Cardiac arrest and sudden cardiac death. In: Zipes D, Libby P, Bonow R, Braunwald E, eds. Heart disease: a textbook of cardiovascular medicine. 7th ed. Philadelphia, PA: WB Saunders, 2005: 865-908.
2. Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998; 97: 596-601.
3. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001; 22: 1374-450.
4. Straus SM, Bleumink GS, Dieleman JP, van der Lei J, Stricker BH, Sturkenboom MC. The incidence of sudden cardiac death in the general population. J Clin Epidemiol 2004; 57: 98-102.
5. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation 1998; 98: 2334-51.
6. Greenberg H, Case RB, Moss AJ, Brown MW, Carroll ER, Andrews ML, for the MADIT-II Investigators. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol 2004; 43: 1459-65.
7. Buxton AE, Lee KL, Hafley GE, et al, for the MUSTT Investigators. Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease: an analysis of patients enrolled in the Multicenter Unsustained Tachycardia Trial. Circulation 2002; 106: 2466-72.
8. Kadish A, Dyer A, Daubert JP, et al, for the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350: 2151-8.
9. Grimm W, Christ M, Bach J, Muller HH, Maisch B. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. Circulation 2003; 108: 2883-91.
10. Cannom DS, Prystowsky EN. Management of ventricular arrhythmias: detection, drugs, and devices. JAMA 1999; 281: 172-9.
11. Caffrey SL, Willoughby PJ, Pepe PE, Becker LB. Public use of automated external defibrillators. N Engl J Med 2002; 347: 1242-7.
12. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102: 748-54.
13. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337: 1576-83.
14. Connolly SJ, Gent M, Roberts RS, et al. Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101: 1297-302.
15. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk of ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335: 1933-40.
16. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999; 341: 1882-90.
17. Schmitt C, Barthel P, Ndrepepa G, et al. Value of programmed ventricular stimulation for prophylactic internal cardioverter-defibrillator implantation in postinfarction patients preselected by noninvasive risk stratifiers. J Am Coll Cardiol 2001; 37: 1901-7.
18. Moss AJ, Zareba W, Hall WJ, et al, for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-83.
19. Bristow MR, Saxon LA Boehmer J, et al, for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with and without an implantable defibrillator in advance chronic heart failure. N Engl J Med 2004; 350: 2140-50.
20. Bardy GH, Lee KL, Mark DB, et al, for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-37.
21. Bansch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 2002; 105: 1453-8.
22. Strickberger SA, Hummel JD, Bartlett TG, et al, for the AMIOVIRT Investigators. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT. J Am Coll Cardiol 2003; 41: 1707-12.
23. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 guidelines for the evaluation and management of heart failure). J Am Coll Cardiol 2005; 46: el-e82.
24. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: full text (update 2005). The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Available at http://www.escardio.org
25. Lunati M, Bongiorni MG, Borini G, et al. Linee guida AIAC 2006 all'impianto di pacemaker, dispositivi per la resincronizzazione cardiaca (CRT) e defibrillatori automatici impiantabili (ICD). Giornale Italiano di Aritmologia e Cardiostimolazione 2005; 8: 1-58.
26. Reynolds MR, Josephson ME. MADIT II (Second Multicenter Automated Defibrillator Implantation Trial) debate: risk stratification, costs, and public policy. Circulation 2003; 108: 1779-83.
27. Moss AJ. Everyone with an ejection fraction ≤30% should receive an implantable cardioverter-defibrillator. Circulation 2005; 111: 2542-8.
28. Buxton A. Not everyone with an ejection fraction ≤30% should receive an implantable cardioverter-defibrillator. Circulation 2005; 111: 2537-42.
29. Fisher JD. Who needs a defibrillator? The beat goes on. J Am Coll Cardiol 2005; 46: 1727-8.
30. Prystowsky EN. Primary prevention of sudden cardiac death: the time of your life. Circulation 2004; 109: 1073-5.
31. Stevenson WG, Epstein LM. Predicting sudden death risk for heart failure patients in the implantable cardioverter-defibrillator age. Circulation 2003; 107:514-6.
32. Brennan FJ. Ethical issues with implantable defibrillators. Pacing Clin Electrophysiol 2004; 27: 897-900.
33. Centers for Medicare and Medicaid Services. Decision memorandum for implantable cardioverter defibrillators (CAG-00157N). Available at http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=39.
34. Ezekowitz JA, Armstrong PW, McAlister FA. Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. Ann Intern Med 2003; 138: 445-52.
35. Moss AJ. Comments on ethical issues with implantable defibrillators by F. James Brennan [comment]. Pacing Clin Electrophysiol 2004; 27: 900.
36. Rahmoeller G. Comments on ethical issues with implantable defibrillators by E James Brennan [comment]. Pacing Clin Electrophysiol 2004; 27: 899.
37. Disertori M, El-Sherif N. Primary prevention of sudden cardiac death. Do we need to implant a defibrillator in all patients with low ejection fraction? Ital Heart J 2004; 5: 643-7.
38. Mant D. Can randomised trials inform clinical decisions about individual patients? Lancet 1999; 353: 743-6.
39. Zipes DP. Implantable cardioverter-defibrillator. A Volkswagen or a Roll Royce: how much will we pay to save a life? Circulation 2001; 103: 1372-4.
40. McClellan MB, Tunis SR. Medicare coverage of ICDs. N Engl J Med 2005; 352: 222-4.
41. Krahn AD, Connolly SJ, Roberts RS, Gent M, for the ATMA Investigators. Diminishing proportional risk of sudden death with advancing age: implications for prevention of sudden death. Am Heart J 2004; 147: 837-40.
42. Escobedo LG, Zack MM. Comparison of sudden and non-sudden coronary deaths in the United States. Circulation 1996; 93: 2033-6.
43. Owen A. Life expectancy of elderly and very elderly patients with chronic heart failure. Am Heart J 2006; 151: 1322.
44. Huynh BC, Rovner A, Rich MW. Long-term survival in elderly patients hospitalized for heart failure: 14-year follow-up from a prospective ranmdomized trial. Arch Intern Med 2006; 166: 1892-8.
45. US Social Security Administration. Actuarial Publications. Period Life Table 2003. Available at http://www.ssa.gov/OACT/STATS/table4c6.html.
46. Bouvy ML, Heerdink ER, Leufkens HG, Hoes AW. Predicting mortality in patients with heart failure: a pragmatic approach. Heart 2003; 89: 605-9.
47. Mozaffarian D, Anker SD, Anand I, et al. Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation 2007; 116: 392-8.
48. Parkash R, Stevenson WG, Epstein LM, Maisel WH. Predicting early mortality after implantable defibrillator implantation: a clinical risk score for optimal patient selection. Am Heart J 2006; 151: 397-403.
49. Yamoz MJ, Curtis AB. Why cardioverter-defibrillator implantation might not be the best idea for your elderly patient. Am J Geriatr Cardiol 2006; 15: 367-71.
50. Lee DS, Tu JV, Austin PC, et al. Effect of cardiac and non-cardiac conditions on survival after defibrillator implantation. J Am Coll Cardiol 2007; 49: 2408-15.
51. Cleland JG, Thygesen K, Uretsky BF, et al, for the ATLAS Investigators. Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study. Eur Heart J 2001; 22: 1601-12.
52. Grimm W. Clinical trials of prophylactic implantable defibrillator therapy in patients with nonischemic cardiomyopathy: what we have learned and what can we expect from future trials? Card Electrophysiol Rev 2003; 7: 463-7.
53. Daubert JP, Sesselberg HW, Huang DT. Implantable cardioverter-defibrillators for primary prevention: how do the data pertain to the aged? Am J Geriatr Cardiol 2006; 15: 88-92.
54. Torp-Pedersen C, Poole-Wilson PA, Swedberg K, et al, for the COMET Investigators. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure - COMET. Am Heart J 2005; 149: 370-6.
55. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.
56. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.
57. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
58. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-55.
59. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
60. Al-Khatib SM, Sanders GD, Mark DB, et al, for an expert panel participating in a Duke Clinical Research Institute-sponsored conference. Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. Am Heart J 2005; 149: 1020-34.
61. Luu M, Stevenson WG, Stevenson LW, Baron K, Walden J. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation 1989; 80: 1675-80.
62. Kempf FC Jr, Josephson ME. Cardiac arrest recorded on ambulatory electrocardiograms. Am J Cardiol 1984; 53: 1577-82.
63. Pires LA, Lehmann MH, Steinman RT, Baga JJ, Schuger CD. Sudden death in implantable cardioverter-defibrillator recipients: clinical context, arrhythmic events and device responses. J Am Coll Cardiol 1999; 33: 24-32.
64. Packer M. Lack of relation between ventricular arrhythmias and sudden death in patients with chronic heart failure. Circulation 1992; 85 (1 Suppl): I50-I56.
65. Dorian P, Connolly S, Yusuf S. The impact of left ventricular dysfunction on outcomes with the implantable defibrillator. Am Heart J 1994; 127 (4 Pt 2): 1159-63.
66. Eisenberg MS, Horwood BT, Cummins RO, Reynolds-Haertle R, Hearne TR. Cardiac arrest and resuscitation: a tale of 29 cities. Ann Emerg Med 1990; 19: 179-86.
67. Saxon LA, Bristow MR, Boehmer J, et al. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial. Circulation 2006; 114: 2766-72.
68. Tomaselli GF, Zipes DP. What causes sudden death in heart failure? Circ Res 2004; 95: 754-63.
69. Mehta D, Curwin J, Gomes JA, Fuster V. Sudden death in coronary artery disease: acute ischemia versus myocardial substrate. Circulation 1997; 96: 3215-23.
70. Maseri A, Chierchia S. Coronary artery spasm: demonstration, definition, diagnosis, and consequences. Prog Cardiovasc Dis 1982; 25: 169-92.
71. Pepine CJ, Morganroth J, McDonald JT, Gottlieb SO. Sudden death during ambulatory electrocardiographic monitoring. Am J Cardiol 1991; 68: 785-8.
72. Zoni-Berisso M, Cavallini A, Iannetti M. Sudden death during continuous Holter monitoring out of hospital after nitroglycerin assumption. Am J Cardiol 1984; 54: 677-9.
73. Bayes de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989; 117: 151-9.
74. Uretsky BF, Thygesen K, Armstrong PW, et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial. Circulation 2000; 102: 611-6.
75. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336: 1276-82.
76. Davies MJ. Anatomic features in victims of sudden coronary death: coronary artery pathology. Circulation 1992; 85 (1 Suppl): I19-I24.
77. Elhendy A, Chapman S, Porter TR, Windle J. Association of myocardial ischemia with mortality and implantable cardioverter-defibrillator therapy in patients with coronary artery disease at risk of arrhythmic death. J Am Coll Cardiol 2005; 46: 1721-6.
78. Singh JP, Hall WJ, McNitt S, et al, for the MADIT-II Investigators. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). J Am Coll Cardiol 2005; 46: 1712-20.
79. Paganelli F, Barnay P, Imbert-Joscht I, et al. Influence of residual myocardial ischaemia on induced ventricular arrhythmias following a first acute myocardial infarction. Eur Heart J 2001; 22: 1931-7.
80. Meissner MD, Akhtar M, Lehmann MH. Nonischemic sudden tachyarrhythmic death in atherosclerotic heart disease. Circulation 1991; 84: 905-12.
81. Bourke JP, Richards DA, Ross DL, Wallace EM, McGuire MA, Uther JB. Routine programmed electrical stimulation in survivors of acute myocardial infarction for prediction of spontaneous ventricular tachyarrhythmias during followup: results, optimal stimulation protocol and cost-effective screening. J Am Coll Cardiol 1991; 18: 780-8.
82. Cripps T, Bennett ED, Camm AJ, Ward DE. Inducibility of sustained monomorphic ventricular tachycardia as a prognostic indicator in survivors of recent myocardial infarction: a prospective evaluation in relation to other prognostic variables. J Am Coll Cardiol 1989; 14: 289-96.
83. Iesaka Y, Nogami A, Aonuma K, et al. Prognostic significance of sustained monomorphic ventricular tachycardia induced by programmed ventricular stimulation using up to triple extrastimuli in survivors of acute myocardial infarction. Am J Cardiol 1990; 65: 1057-63.
84. Zoni-Berisso M, Molini D, Mela GS, Vecchio C. Value of programmed ventricular stimulation in predicting sudden death and sustained ventricular tachycardia in survivors of acute myocardial infarction. Am J Cardiol 1996; 77: 673-80.
85. Pedretti R, Etro MD, Laporta A, Sarzi Braga S, Carù B. Prediction of late arrhythmic events after acute myocardial infarction from combined use of noninvasive prognostic variables and inducibility of sustained monomorphic ventricular tachycardia. Am J Cardiol 1993; 71: 1131-41.
86. Geelen P, Primo J, Wellens F, Brugada P. Coronary artery bypass grafting and defibrillator implantation in patients with ventricular tachyarrhythmias and ischemic heart disease. Pacing Clin Electrophysiol 1999; 22: 1132-9.
87. Kuchar DL, Thorburn CW, Sammel NL. Prediction of serious arrhythmic events after myocardial infarction: signal-averaged electrocardiogram, Holter monitoring and radionuclide ventriculography. J Am Coll Cardiol 1987; 9: 531-8.
88. El-Sherif N, Ursell SN, Bekheit S, et al. Prognostic significance of the signal-averaged ECG depends on the time of recording in the postinfarction period. Am Heart J 1989; 118: 256-64.
89. Bloomfield DM, Bigger JT, Steinman RC, et al. Microvolt T-wave alternans and the risk of death or sustained ventricular arrhythmias in patients with left ventricular dysfunction. J Am Coll Cardiol 2006; 47: 456-63.
90. La Rovere MT, Pinna GD, Maestri R, et al. Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation 2003; 107: 565-70.
91. Huikuri HV, Valkama JO, Airaksinen KE, et al. Frequency domain measures of heart rate variability before the onset of nonsustained and sustained ventricular tachycardia in patients with coronary artery disease. Circulation 1993; 87: 1220-8.
92. Bailey JJ, Berson AS, Handelsman H, Hodges M. Utility of current risk stratification tests for predicting major arrhythmic events after myocardial infarction. J Am Coll Cardiol 2001; 38: 1902-11.
93. Narayan SM. T-wave alternans and the susceptibility to ventricular arrhythmias. J Am Coll Cardiol 2006; 47: 269-81.
94. Gehi AK, Stein RH, Metz LD, Gomes JA. Microvolt T-wave alternans for the risk stratification of ventricular tachyarrhythmic events: a meta-analysis. J Am Coll Cardiol 2005; 46: 75-82.
95. Galinier M, Pathak A, Fourcade J, et al. Depressed low frequency power of heart rate variability is an independent predictor of sudden death in chronic heart failure. Eur Heart J 2000; 21: 475-82.
96. Bilchick KC, Fetics B, Djoukeng R, et al. Prognostic value of heart rate variability in chronic congestive heart failure (Veterans Affairs' Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure). Am J Cardiol 2002; 90: 24-8.
97. Guzzetti S, La Rovere MT, Pinna GD, et al. Different spectral components of 24 h heart rate variability are related to different mores of death in chronic heart failure. Eur Heart J 2005; 26: 357-62.
98. Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 1998; 98: 1510-6.
99. Makikallio TH, Huikuri H, Hintze U, et al, for the DIAMOND Study Group. Fractal analysis and time- and frequency-domain measures of heart rate variability as predictors of mortality in patients with heart failure. Am J Cardiol 2001; 87: 178-82.
100. Chow T, Kereiakes DJ, Bartone C, et al. Microvolt T-wave alternans identifies patients with ischemic cardiomyopathy who benefit from implantable cardioverter-defibrillator therapy. J Am Coll Cardiol 2007; 49: 50-8.
101. Makikallio TH, Barthel P, Schneider R, et al. Frequency of sudden cardiac death among acute myocardial infarction survivors with optimized medical and revascularization therapy. Am J Cardiol 2006; 97: 480-4.
102. McMurray J, Kober L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 2005; 45: 525-30.
103. Cintron G, Johnson G, Francis G, Cobb F, Cohn JN. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The VHeFT VA Cooperative Studies Group. Circulation 1993; 87 (6 Suppl): VI17-VI23.
104. Metra M, Nodari S, Parrinello G, Giubbini R, Manca C, Dei Cas L. Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. Am Heart J 2003; 145: 292-9.
105. Zoni Berisso M, Silvestri D. Risk stratification after acute myocardial infarction: what is the usefulness of programmed ventricular stimulation? In: Raviele A, ed. Cardiac Arrhythmias 1997. Milano: Springer, 1998: 213-21.
106. Zoni Berisso M, Molini D, Viani S, Mela GS, Delfino L. Noninvasive prediction of sudden death and sustained ventricular tachycardia after acute myocardial infarction using a neural network algorithm. Ital Heart J 2001; 2: 612-20.
107. Hohnloser SH, Kuck KH, Dorian P, et al, for the DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351: 2481-8.
108. Raviele A, Bongiorni MG, Brignole M, et al, for the BEST+ICD Trial Investigators. Early EPS/ICD strategy in survivors of acute myocardial infarction with severe left ventricular dysfunction on optimal beta-blocker treatment. The Beta-Blocker Strategy plus ICD trial. Europace 2005; 7: 327-37.
109. Gorgels AP, Gijsbers C, de Vreede-Swagemakers J, Lousberg A, Wellens HJ. Out-of-hospital cardiac arrest - the relevance of heart failure. The Maastricht Circulatory Arrest Registry. Eur Heart J 2003; 24: 1204-9.
110. Stecker EC, Vickers C, Waltz J, et al. Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. J Am Coll Cardiol 2006; 47: 1161-6.
111. Daubert JP, Zareba W, Hall WJ, et al, for the MADIT II Study Investigators. Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients. J Am Coll Cardiol 2006; 47: 98-107.
112. Gomes JA, Cain ME, Buxton AE, Josephson ME, Lee KL, Hafley GE. Prediction of long-term outcomes by signal-averaged electrocardiography in patients with unsustained ventricular tachycardia, coronary artery disease, and left ventricular dysfunction. Circulation 2001; 104: 436-41.
113. Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 1997; 337: 1569-75.
114. Pires LA, Hafley GE, Lee KL, et al, for the Multicenter Unsustained Tachycardia Trial Investigators. Prognostic significance of nonsustained ventricular tachycardia identified postoperatively after coronary bypass surgery in patients with left ventricular dysfunction. J Cardiovasc Electrophysiol 2002; 13: 757-63.
115. Holmes DR Jr, Davis KB, Mock MB, et al. The effect of medical and surgical treatment on subsequent sudden cardiac death in patients with coronary artery disease: a report from the Coronary Artery Surgery Study. Circulation 1986; 73: 1254-63.
116. European Coronary Surgery Study Group. Long-term results of prospective randomised study of coronary artery bypass surgery in stable angina pectoris. Lancet 1982; 2: 1173-80.
117. Veenhuyzen GD, Singh SN, McAreavey D, Shelton BJ, Exner DV. Prior coronary artery bypass surgery and risk of death among patients with ischemic left ventricular dysfunction. Circulation 2001; 104: 1489-93.
118. Ansalone G, Giannantoni P, Santini M. Stratificazione prognostica del rischio aritmico nella cardiomiopatia dilatativa non ischemica. G Ital Cardiol 1998; 28: 1288-302.
119. Baker RL, Koelling TM. Prognostic value of ambulatory electrocardiography monitoring in patients with dilated cardiomyopathy. J Electrocardiol 2005; 38: 64-8.
120. Grimm W, Christ M, Maisch B. Long tons of non-sustained ventricular tachycardia on 24-hour ambulatory electrocardiogram predict major arrhythmic events in patients with idiopathic dilated cardiomyopathy. Pacing Clin Electrophysiol 2005; 28 (Suppl 1): S207-S210.
121. Grimm W, Hoffmann J, Menz V, Luck K Maisch B. Programmed ventricular stimulation for arrhythmia risk prediction in patients with idiopathic dilated cardiomyopathy and nonsustained ventricular tachycardia. J Am Coll Cardiol 1998; 32: 739-45.
122. Turitto G, Ahuja RK, Caref EB, El-Sherif N. Risk stratification for arrhythmic events in patients with nonischemic dilated cardiomyopathy and nonsustained ventricular tachycardia: role of programmed ventricular stimulation and signal-averaged electrocardiogram. J Am Coll Cardiol 1994; 24: 1523-8.
123. Brembilla-Perrot B, Terrier de la Chaise A, Jacquemin L, Beurrier D, Houplon P. The signal-averaged electrocardiogram is of limited value in patients with bundle branch block and dilated cardiomyopathy in predicting inducible ventricular tachycardia or death. Am J Cardiol 1997; 79: 154-9.
124. Silverman ME, Pressel MD, Brackett JC, Lauria SS, Gold MR, Gottlieb SS. Prognostic value of the signal-averaged electrocardiogram and a prolonged QRS in ischemic and nonischemic cardiomyopathy. Am J Cardiol 1995; 75: 460-4.
125. Hoffmann J, Grimm W, Menz V, Knop U, Maisch B. Heart rate variability and major arrhythmic events in patients with idiopathic dilated cardiomyopathy. Pacing Clin Electrophysiol 1996; 19 (11 Part 2): 1841-4.
126. Rashba EJ, Estes NA, Wang P, et al. Preserved heart rate variability identifies low-risk patients with nonischemic dilated cardiomyopathy: results from the DEFINITE trial. Heart Rhythm 2006; 3: 281-6.
127. Salerno-Uriarte JA, De Ferrari GM, Klersy C, et al, for the ALPHA Study Group Investigators. Prognostic value of T-wave alternans in patients with heart failure due to nonischemic cardiomyopathy: results of the ALPHA Study. J Am Coll Cardiol 2007; 50: 1896-904.
128. Albert CM, Ma J, Rafai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002; 105: 2595-9.
129. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635-41.
130. Yeh ET, Anderson HV, Pasceri V, Willerson JT. C-reactive protein: linking inflammation to cardiovascular complications. Circulation 2001; 104: 974-5.
131. Biasucci LM, Giubilato G, Biondi-Zoccai G, et al. C-reactive protein is associated with malignant ventricular arrhythmias in patients with ischaemia with implantable cardioverter-defibrillator. Heart 2006; 92: 1147-8.
132. Shehab AM, MacFadyen RJ, McLaren M, Tavendale R, Belch JJ, Struthers AD. Sudden unexpected death in heart failure may be preceded by short-term, intraindividual increases in inflammation and in autonomic dysfunction: a pilot study. Heart 2004; 90: 1263-8.
133. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105: 2392-7.
134. Vrtovec B, Delgado R, Zewail A, Thomas CD, Richartz BM, Radovancevic B. Prolonged QTc interval and high B-type natriuretic peptide levels together predict mortality in patients with advanced heart failure. Circulation 2003; 107: 1764-9.
135. Verma A, Kilicaslan F, Martin DO, et al. Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies. Heart 2006; 92: 190-5.
136. De Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014-21.
137. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-8.
138. Spooner PM, Zipes DP. Sudden death predictors: an inflammatory association. Circulation 2002; 105: 2574-6.
139. Chen HH, Burnett JC. Natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep 2000; 2: 198-205.
140. Franz MR, Cima R, Wang D, Profitt D, Kurz R. Electrophysiological effects of myocardial stretch and mechanical determinants for stretch-activated arrhythmias. Circulation 1992; 86: 968-78.
141. Toth M, Vuorinen KH, Vuolteenaho O, et al. Hypoxia stimulates release of ANP and BNP from perfused rat ventricular myocardium. Am J Physiol 1994; 266 (4 Pt 2): H1572-H1580.
142. D'Souza SP, Davis M, Baxter GF. Autocrine and paracrine actions of natriuretc peptides in the heart. Pharmacol Ther 2004; 101: 113-29.
143. Goetze JP, Christoffersen C, Perko M, et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 2003; 17: 1105-7.
144. Schnabel R, Lubos E, Rupprecht HJ, et al. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results of the AtheroGene study. J Am Coll Cardiol 2006; 47: 552-8.
145. Marumoto K, Hamada M, Hiwada K. Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris. Clin Sci (Lond) 1995; 88: 551-6.
146. Centers for Medicare and Medicaid Services. Decision memorandum for microvolt T-wave alternans (CAG00293N). Available at http://www.cms.hhs.gov/mcd/view draftdecisionmemo.asp?id=165.
147. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/ American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006; 8: 746-837.
148. Solomon SD, Zelenkofske S, McMurray JJ, et al, for the Valsartan in Acute Myocardial Infarction Trial (VALIANT) Investigators. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005; 352: 2581-8.
149. Al-Khatib SM, Stebbins AL, Califf RM, et al. Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial. Am Heart J 2003; 145: 515-21.
150. Cleland JG, Daubert JC, Erdmann E, et al, for the Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-49.
151. Cleland JG, Daubert JC, Erdmann E, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the Cardiac Resynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 2006; 27: 1928-32.
152. Tavazzi L. A proposito di defibrillatori impiantabili e linee guida. G Ital Cardiol 2006; 7: 228-33.
153. Boutitie F, Boissel JP, Connolly S, et al. Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. Circulation 1999; 99: 2268-75.
154. Sim I, McDonald KM, Lavori PW, Norbutas CM, Hlatky MA. Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation 1997; 96: 2823-9.
155. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997; 349: 667-74.
156. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997; 350: 1417-24.
157. Alboni P. L'associazione amiodarone-betabloccanti può rappresentare un trattamento alternativo nei pazienti a rischio di morte improvvisa nei quali non è chiaramente dimostrato un beneficio del defibrillatore impiantabile. Ital Heart J Suppl 2002; 3: 337-43.
158. May CD, Smith PR, Murdock CJ, Davis MJ. The impact of the implantable cardioverter defibrillator on quality-of-life. Pacing Clin Electrophysiol 1995; 18: 1411-8.
159. Hamilton GA, Carroll DL. The effects of age on quality of life in implantable cardioverter defibrillator recipients. J Clin Nursing 2004; 13: 194-200.
160. Salukhe TV, Dimopoulos K, Sutton R, Coats AJ, Piepoli M, Francis DP. Life-years gained from defibfillation implantation: markedly nonlinear increase during 3 years of follow-up and its implications. Circulation 2004; 109: 1848-53.
161. Cabell CH, Heidenreich PA, Chu VH, et al. Increasing rates of cardiac device infections among Medicare beneficiaries: 1990-1999. Am Heart J 2004; 147: 582-6.
162. Maisel WH, Moynahan M, Zuckerman BD, et al. Pacemaker and ICD generator malfunctions: analysis of Food and Drug Administration annual reports. JAMA 2006; 295: 1901-6.
163. Gould PA, Krahn AD, for the Canadian Heart Rhythm Society Working Group on Device Advisories. Complications associated with implantable cardioverter-defibrillator replacement in response to device advisories. JAMA 2006; 295: 1907-11.
164. FNOMCeO. II nuovo Codice di Deontologia Medica. La Professione: Medicina, Scienza, Etica e Società 2006; VIII (numero 0): 48-81.
165. Cleland JG, Swedberg K, Follath F, et al, for the Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24: 442-63.
166. Chen L, Hay JW. Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure. Cardiovasc Drugs Ther 2004; 18: 161-70.
167. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005; 353: 1471-80.
168. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators in a MADIT II population. Blue Cross and Blue Shield Association: Technology Evaluation Center, Assessment Program 2004; 19: 1-25. Available at http://www.bcbs.com.
169. Weiss JP, Saynina O, McDonald KM, McClellan MB, Hlatky MA. Effectiveness and cost-effectiveness of implantable cardioverter defibrillators in the treatment of ventricular arrhythmias among Medicare beneficiaries. Am J Med 2002; 112: 519-27.
170. National Institute for Health and Clinical Excellence. Implantable cardioverter defibrillators (ICDs) for the treatment of arrhythmias (review of technology appraisal 11). Available at http://www.nice.org.uk/ TA095.
171. Hay J, LaBree L, Luo R, et al. Cost-effectiveness of preventive occupational therapy for independent-living older adults. J Am Geriatr Soc 2002; 50: 1381-8.
172. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ 1997; 16: 1-31.
173. Graham JD, Corso PS, Morris JM, Segui-Gomez M, Weinstein MC. Evaluating the cost-effectiveness of clinical and public health measures. Annu Rev Public Health 1998; 19: 125-52.
174. Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998; 13: 716-7.
175. Neumann PJ, Rosen AB, Weinstein MC. Medicare and cost-effectiveness analysis. N Engl J Med 2005; 353: 1516-22.